Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid

Cancer Research

Volumn 59, Issue 3, 1999, Pages 521-524

  McCormick, David L ^a   Rao, K V N ^a   Steele, Vernon E ^b   Lubet, Ronald A ^b   Kelloff, Gary J ^b   Bosland, Maarten C ^c  

^a IIT RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CYPROTERONE ACETATE; RETINOID X RECEPTOR; TESTOSTERONE PROPIONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CYPROTERONE ACETATE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHYLNITROSOUREA; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; TESTOSTERONE; TRETINOIN;

EID: 0033082447     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. McCormick, D. L., and Moon, R. C. Vitamin A deficiency and cancer. In: J. C. Bauernfeind (ed.), Vitamin A Deficiency and Its Control, pp. 245-284. New York: Academic Press, 1986.
2. Lotan, R. Retinoids in cancer chemoprevention. FASEB J., 10: 1031-1039, 1996.
3. Heyman, R. A., Mangelsdorf, D. J., Dyck, J. A., Stein, R. B., Eichele, G., Evans, R. M., and Thaller, C. 9-cis-Retinoic acid is a high affinity ligand for the retinoid X receptor. Cell, 68: 397-406, 1992.
4. Levin, A. A., Sturzenbecker, L. J., Kazmer, S., Bosakowski, T., Huselton, C., Allenby, G., Speck, J., Kratzeisen, C., Rosenberger, M., Lovey, A., and Grippo, J. F. 9-cis Retinoic acid stereoisomer binds and activates the nuclear receptor RXRα. Nature (Lond.), 355: 359-361, 1992.
5. Blutt, S. E., Allegretto, E. A., Pike, J. W., and Weigel, N. L. 1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology, 138: 1491-1497, 1997.
6. Rubin, M., Fenig, E., Rosenauer, A., Menendez-Botet, C., Achkar, C., Bentel, J. M., Yahalom, J., Mendelsohn, J., and Miller, W. H., Jr. 9-cis-Retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res., 54: 6549-6556, 1994.
7. Gottardis, M. M., Lamph, W. W., Shalinsky, D. R., Wellstein, A., and Heyman, R. A. The efficacy of 9-cis-retinoic acid in experimental models of cancer. Breast Cancer Res. Treat., 38: 85-96, 1996.
8. Lutzky, J., Vujicic, M., Yamanishi, D. T., and Bhalla, K. Antiproliferative effects of all-trans-retinoic acid (tRA) and 9-cis-retinoic acid (9-cisRA) on human lymphoid cell lines. Proc. Am. Assoc. Cancer Res., 34: 292, 1993.
9. Guzey, M., Demirpence, E., Criss, W., and DeLuca, H. F. Effects of retinoic acid (M-trans and 9-cis) on tumor progression in small-cell lung carcinoma. Biochem. Biophys. Res. Commun., 242: 369-375, 1998.
10. Giannini, F., Maestro, R., Vukosavljevic, T., Pomponi, F., and Boiocchi, M. All-trans, 13-cis, and 9-cis retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: implications for in vivo retinoic acid use. Int. J. Cancer, 70: 194-200, 1997.
11. Anzano, M. A., Byers, S. W., Smith, J. M., Peer, C. W., Mullen, L. T., Brown, C. C., Roberts, A. B., and Sporn, M. B. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res., 54: 4614-4617, 1994.
12. Anzano, M. A., Peer, C. W., Smith, J. M., Mullen, L. T., Shrader, M. W., Logsdon, D. L., Driver, C. L., Brown, C. C., Roberts, A. B., and Sporn, M. B. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst., 88: 123-125, 1996.
13. Zheng, Y., Kramer, P. M., Olson, G., Lubet, R. A., Steele, V. E., Kelloff, G. J., and Pereira, M. A. Prevention by retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. Carcinogenesis (Lond.), 18: 2119-2125, 1997.
14. Rizvi, N. A., Marshall, J. L., Ness, E., Yoe, J., Gill, G. M., Truglia, J. A., Loewen, G. R., Jaunakais, D., Ulm, E. H., and Hawkins, M. J. Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer. Clin. Cancer Res., 4: 1437-1442, 1998.
15. McCormick, D. L., Rao, K. V. N., Dooley, L., Steele, V. E., Lubet, R. A., Kelloff, G. J., and Bosland, M. C. Influence of N-methyl-N-nitrosourea, testosterone, and W-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats. Cancer Res., 58: 3282-3288, 1998.
16. Bosland, M. C. Age-related lesions in the male accessory sex glands and penis of the rat. In: U. Mohr, D. L. Dungworth, and C. C. Capen (eds.), Monographs on Pathobiology of the Aging Rat, Vol. 1, pp. 443-467. Washington, DC: ILSI Press, 1992.
17. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
18. Jones, G. W. Prostate cancer magnitude of the problem. American College of Surgeons database and epidemiologic study. Cancer (Phila.), 71: 887-890, 1993.
19. Gottardis, M. M., Bischoff, E. D., Shirley, M. A., Wagoner, M. A., Lamph, W. W., and Heyman, R. A. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res., 56: 5566-5570, 1996.
20. Bischoff, E. D., Gottardis, M. M., Moon, T. E., Heyman, R. A., and Lamph, W. W. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (targretin) causes complete regression of mammary carcinoma. Cancer Res., 58: 479-484, 1998.
21. McCormick, D. L., Burns, F. J., and Albert, R. E. Inhibition of rat mammary carcinogenesis by short dietary exposure to retinyl acetate. Cancer Res., 40: 1140-1143, 1980.
22. McCormick, D. L., Burns, F. J., and Albert, R. E. Inhibition of benzo(α)pyrene-induced mammary carcinogenesis by retinyl acetate. J. Natl. Cancer Inst., 66: 559-564, 1981.
23. Achkar, C. C., Bentel, J. M., Boylan, J. F., Scher, H. I., Gudas, L. J., and Miller, W. H., Jr. Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. Drug. Metab. Dispos., 22: 451-458, 1994.
24. Howell, S. R., Shirley, M. A., and Ulm, E. H. Effects of retinoid pretreatment of rats on hepatic microsomal metabolism and cytochromes P450. Correlation between retinoic acid receptor/retinoid X receptor selectivity and effects on metabolic enzymes. Drug Metab. Dispos., 26: 234-239, 1998.
25. Cooney, A., Leng, X., Tsai, S. Y., O'Malley, B. W., and Tsai, M. J. Multiple mechanisms of chicken ovalbumin upstream promoter transcription factor-dependent repression of activation by the vitamin D, thyroid hormone, and retinoic acid receptors. J. Biol. Chem., 268: 4152-4160, 1993.
26. Carlberg, C., and Saurai, J. H. Vitamin D-retinoid association: molecular basis and clinical applications. J. Invest. Dermatol. Symp. Proc., 1: 82-87, 1996.
27. Gearing, K. L., Gottlicher, M., Teboul, M., Widmark, E., and Gustafsson, J. A. Interaction of the peroxisome proliferator-activated receptor and the retinoid X receptor. Proc. Natl. Acad. Sci. USA. 90: 1440-1444, 1993.
28. Mangelsdorf, D. J., and Evans, R. M. The RXR heterodimers and orphan receptors. Cell, 83: 841-850, 1995.
29. Janowski, B. A., Willey, P. J., Devi, T. R., Falck, J. R., and Mangelsdorf, D. R. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature (Lond.), 383: 728-731, 1996.
30. Wiebel, F. F., and Gustafsson, J. A. Heterodimeric interaction between retinoid X receptor a and orphan nuclear receptor OR1 reveals dimerization induced activation as a novel mechanism of nuclear receptor activation. Mol. Cell. Biol., 17: 3977-3986, 1997.